EFNA1 and glioblastoma: To date, EPHA2-targeted therapy options in GBM include preclinical, experimental immunotherapy with EPHA2-specific T cells and infusion with ephrin A1 (EFNA1)-based bacterial cytotoxin targeted to EPHA2 [121,122].